Search | Clinical Trials Finder

Conditions: Stem Cell Surveillance
Interventions: Anthocyanin-rich berry extract, Anthocyanin-rich flower/leaf extract, Berry /leaf blend, Placebo; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: MEM 3454, Placebo for MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more

Conditions: Obesity, Morbid Obesity
Interventions: Transcend II Model 8848; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Gainsville, Florida • Chicago, Illinois + 5 more

Conditions: Crohn's Disease
Interventions: Placebo, TD-1473; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 44
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 39 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Climacteric; Menorrhagia, Menopausal, Menopause
Interventions: 50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC, Placebo and then 100 mg PYC; Dietary Supplement
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Gresham, Oregon • Portland, Oregon • Tualatin, Oregon

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Allo-hMSCs, Placebo; Drug
Lead sponsor: Longeveron Inc.; Industry
Eligibility: Up to 30 Days
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Molluscum Contagiosum
Interventions: SB206 12%, Placebo; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 35
States / cities: Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more

Conditions: Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Interventions: SR604, Placebo; Drug
Lead sponsor: Equilibra Bioscience LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: GK1-399 (formerly TTP399), Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • Chula Vista, California • DeLand, Florida + 8 more

Conditions: Atopic Dermatitis
Interventions: S-777469 400 mg, S-777469 800 mg, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more

Conditions: Triple Negative Breast Cancer
Interventions: Cyclophosphamide, Placebo, Doxorubicin, Paclitaxel, Carboplatin, Veliparib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 61
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more

Conditions: Asthma
Interventions: JNJ39758979, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 14
States / cities: Scottsdale, Arizona • Cypress, California • Los Angeles, California + 11 more

Conditions: Alzheimer Disease
Interventions: MK-2214, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Glendale, California • Los Alamitos, California • Orange, California + 9 more

Conditions: Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 25 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 475
States / cities: Antioch, California • Berkeley, California • Burlingame, California + 328 more

Conditions: Overweight
Interventions: Dietary Supplements and TR90 Eating Plan, Placebo and Low Fat Eating Plan; Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Fibrosing Interstitial Lung Disease
Interventions: Nerandomilast, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: Pain Associated With Osteoarthritis of the Knee
Interventions: X0002; Drug
Lead sponsor: Techfields Pharma Co. Ltd; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 33
States / cities: Phoenix, Arizona • Yuma, Arizona • Anaheim, California + 29 more

Conditions: Tuberculosis
Interventions: BCG strain Connaught, BCG strain Danish, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Tourette Syndrome
Interventions: Active Treatment, Sham Treatment; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: HIV Infections
Interventions: Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah

Search by objective public record fields.

Acute Effects on Stem Cell Surveillance

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Study of Weight Loss Using Gastric Stimulation in Obese Patients

Efficacy and Safety of TD-1473 in Crohn's Disease

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

A Prospective Study Investigating the Effects of a Novel Weight Management Program

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

Multi-site Transcranial Magnetic Stimulation Therapy of the Supplementary Motor Area in Children With Tourette Syndrome

First Time in Human Study of Long Acting VH4524184 Formulations